ALK and neoplasm: Current efforts are focused on designing ALK inhibitors that provide broader coverage of resistance-associated mutations while exhibiting enhanced CNS penetration, thereby addressing challenges such as compound mutations, bypass signaling activation, and tumor heterogeneity [63].